Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

A strong start to the week
Mon, 6 Apr Closing

The Indian markets ended the day on a firm note as selected index heavy weights led the gains. The <>BSE-Sensex ended higher by 244 points or 0.86% while the <>NSE-Nifty closed higher by 74 points or 0.86%. Midcaps and smallcaps shared the enthusiasm as the representative indices ended higher by 1.1% and 1.4% respectively. Amongst the sectoral indices pharmaceuticals and <>realty stocks were trading firm while the <>banking and <>metal stocks were amongst the key underperformers.

Pharmaceutical stocks ended the day on a firm note led by Sun Pharmaceuticals and Cadila Healthcare. The stock of Sun Pharmaceuticals was on fire today with the same closing higher by 8% and adding as much as 78 points to the gain of the Sensex. Sentiments seem to be buoyed by two key developments - the completion of the Ranbaxy merger as well as the settlement of the Angiomax drug patent litigation with US-based The Medicines Company. With the completion of the latter, it would allow the company to market generic bivalirudin product in the US on 30 June 2019, or earlier in some circumstances. The market for this drug is estimated at US$ 600 m; what is more is that Sun Pharma could possibly enjoy six months exclusive sales on this drug as well. With the surge in the stock price - which hit its all time high figure today - the company has now become the fifth largest company by market capitalisation in the country.

Auto ancillary stocks ended the day on a weak note with Asahi India and Bosch leading the pack of losers. As per a leading business daily, Bosch has declared a lock down at its Jaipur facility due to the ongoing worker unrest at the unit. The company has decided to take this move after output was cut by as much as 70% on account of the workers proceeding on an 'illegal go slow' action since March 19, 2015. Further, the labour union is believed to have gone on a hunger strike since April 2, 2015. As per reports, the company does not expect to see any major issue with meeting its customers' requirements considering that it has the inventory built up, and production from officers who have been trained to work in production. As per the company, it has been in wage settlement negotiations for over 20 months now. While the stock of Bosch continues to trade close to its yearly high price, it has seen some correction in the past few weeks. The stock closed the day lower by about 0.8%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "A strong start to the week". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.